These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1682040

  • 41. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 42. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW.
    Clin Cancer Res; 1995 Aug 01; 1(8):847-57. PubMed ID: 9816054
    [Abstract] [Full Text] [Related]

  • 43. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.
    Yano T, Pinski J, Groot K, Schally AV.
    Cancer Res; 1992 Aug 15; 52(16):4545-7. PubMed ID: 1643647
    [Abstract] [Full Text] [Related]

  • 44. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer.
    Dy DY, Whitehead RH, Morris DL.
    Cancer Res; 1992 Feb 15; 52(4):917-23. PubMed ID: 1737355
    [Abstract] [Full Text] [Related]

  • 45. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 46. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Jul 19; 91(15):7090-4. PubMed ID: 7518926
    [Abstract] [Full Text] [Related]

  • 47. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL.
    Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15836-41. PubMed ID: 14660794
    [Abstract] [Full Text] [Related]

  • 48. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Oct 23; 6(10):4158-65. PubMed ID: 11051271
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

  • 54. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP.
    Qin Y, Ertl T, Cai RZ, Horvàth JE, Groot K, Schally AV.
    Int J Cancer; 1995 Oct 09; 63(2):257-62. PubMed ID: 7591214
    [Abstract] [Full Text] [Related]

  • 55. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV.
    Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934
    [Abstract] [Full Text] [Related]

  • 56. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.
    Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G.
    Invest New Drugs; 2006 Sep 01; 24(5):403-12. PubMed ID: 16505950
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.